We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Gilead Sciences (GILD - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Gilead Sciences is a member of the Medical sector. This group includes 844 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. GILD is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for GILD's full-year earnings has moved 5.97% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, GILD has moved about 5.63% on a year-to-date basis. In comparison, Medical companies have returned an average of 3.85%. This shows that Gilead Sciences is outperforming its peers so far this year.
To break things down more, GILD belongs to the Medical - Biomedical and Genetics industry, a group that includes 352 individual companies and currently sits at #64 in the Zacks Industry Rank. This group has gained an average of 3.46% so far this year, so GILD is performing better in this area.
Investors with an interest in Medical stocks should continue to track GILD. The stock will be looking to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Gilead Sciences (GILD - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Gilead Sciences is a member of the Medical sector. This group includes 844 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. GILD is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for GILD's full-year earnings has moved 5.97% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, GILD has moved about 5.63% on a year-to-date basis. In comparison, Medical companies have returned an average of 3.85%. This shows that Gilead Sciences is outperforming its peers so far this year.
To break things down more, GILD belongs to the Medical - Biomedical and Genetics industry, a group that includes 352 individual companies and currently sits at #64 in the Zacks Industry Rank. This group has gained an average of 3.46% so far this year, so GILD is performing better in this area.
Investors with an interest in Medical stocks should continue to track GILD. The stock will be looking to continue its solid performance.